These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 23081813

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation.
    Olive C, Schulze K, Sun HK, Ebensen T, Horváth A, Toth I, Guzman CA.
    Vaccine; 2007 Feb 26; 25(10):1789-97. PubMed ID: 17229503
    [Abstract] [Full Text] [Related]

  • 3. Protective immunity induced by an intranasal multivalent vaccine comprising 10 Lactococcus lactis strains expressing highly prevalent M-protein antigens derived from Group A Streptococcus.
    Wozniak A, Scioscia N, García PC, Dale JB, Paillavil BA, Legarraga P, Salazar-Echegarai FJ, Bueno SM, Kalergis AM.
    Microbiol Immunol; 2018 Jun 26; 62(6):395-404. PubMed ID: 29704396
    [Abstract] [Full Text] [Related]

  • 4. Microbially synthesized modular virus-like particles and capsomeres displaying group A streptococcus hypervariable antigenic determinants.
    Chuan YP, Wibowo N, Connors NK, Wu Y, Hughes FK, Batzloff MR, Lua LH, Middelberg AP.
    Biotechnol Bioeng; 2014 Jun 26; 111(6):1062-70. PubMed ID: 24338691
    [Abstract] [Full Text] [Related]

  • 5. Oral immunization of mice with engineered Lactobacillus gasseri NM713 strain expressing Streptococcus pyogenes M6 antigen.
    Mansour NM, Abdelaziz SA.
    Microbiol Immunol; 2016 Aug 26; 60(8):527-32. PubMed ID: 27301486
    [Abstract] [Full Text] [Related]

  • 6. Intranasal immunisation of mice with a streptococcal peptide-based vaccine.
    Relf W, Hayman W, Russell-Jones G, Good M.
    Adv Exp Med Biol; 1997 Aug 26; 418():859-61. PubMed ID: 9331788
    [No Abstract] [Full Text] [Related]

  • 7. Structure-based design of broadly protective group a streptococcal M protein-based vaccines.
    Dale JB, Smeesters PR, Courtney HS, Penfound TA, Hohn CM, Smith JC, Baudry JY.
    Vaccine; 2017 Jan 03; 35(1):19-26. PubMed ID: 27890396
    [Abstract] [Full Text] [Related]

  • 8. Combinatorial Synthetic Peptide Vaccine Strategy Protects against Hypervirulent CovR/S Mutant Streptococci.
    Pandey M, Mortensen R, Calcutt A, Powell J, Batzloff MR, Dietrich J, Good MF.
    J Immunol; 2016 Apr 15; 196(8):3364-74. PubMed ID: 26969753
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of novel Streptococcus pyogenes vaccine candidates incorporating multiple conserved sequences from the C-repeat region of the M-protein.
    Bauer MJ, Georgousakis MM, Vu T, Henningham A, Hofmann A, Rettel M, Hafner LM, Sriprakash KS, McMillan DJ.
    Vaccine; 2012 Mar 09; 30(12):2197-205. PubMed ID: 22265945
    [Abstract] [Full Text] [Related]

  • 10. Identification and characterization of a novel heme-associated cell surface protein made by Streptococcus pyogenes.
    Lei B, Smoot LM, Menning HM, Voyich JM, Kala SV, Deleo FR, Reid SD, Musser JM.
    Infect Immun; 2002 Aug 09; 70(8):4494-500. PubMed ID: 12117961
    [Abstract] [Full Text] [Related]

  • 11. Similar ability of FbaA with M protein to elicit protective immunity against group A streptococcus challenge in mice.
    Ma CQ, Li CH, Wang XR, Zeng RH, Yin XL, Feng HD, Wei L.
    Cell Mol Immunol; 2009 Feb 09; 6(1):73-7. PubMed ID: 19254483
    [Abstract] [Full Text] [Related]

  • 12. Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments.
    Dale JB.
    Vaccine; 1999 Jan 09; 17(2):193-200. PubMed ID: 9987154
    [Abstract] [Full Text] [Related]

  • 13. Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococci.
    Good MF, Pandey M, Batzloff MR, Tyrrell GJ.
    Expert Rev Vaccines; 2015 Jan 09; 14(11):1459-70. PubMed ID: 26485214
    [Abstract] [Full Text] [Related]

  • 14. Immunization with a 22-kDa outer membrane protein elicits protective immunity to multidrug-resistant Acinetobacter baumannii.
    Huang W, Yao Y, Wang S, Xia Y, Yang X, Long Q, Sun W, Liu C, Li Y, Chu X, Bai H, Yao Y, Ma Y.
    Sci Rep; 2016 Feb 08; 6():20724. PubMed ID: 26853590
    [Abstract] [Full Text] [Related]

  • 15. Intranasal immunization with recombinant group A streptococcal M protein fragment fused to the B subunit of Escherichia coli labile toxin protects mice against systemic challenge infections.
    Dale JB, Chiang EC.
    J Infect Dis; 1995 Apr 08; 171(4):1038-41. PubMed ID: 7706785
    [Abstract] [Full Text] [Related]

  • 16. Immune response against M protein-conserved region peptides from prevalent group A Streptococcus in a North Indian population.
    Gupta VK, Sekhar S, Dhanda V, Toor D, Kumar R, Chakraborti A.
    J Microbiol Immunol Infect; 2016 Jun 08; 49(3):352-8. PubMed ID: 25087198
    [Abstract] [Full Text] [Related]

  • 17. Clinical and microbiological response of mice to intranasal inoculation with Lactococcus lactis expressing Group A Streptococcus antigens, to be used as an anti-streptococcal vaccine.
    García PC, Paillavil BA, Scioscia N, Dale JB, Legarraga P, Salazar-Echegarai FJ, Bueno SM, Kalergis AM, Wozniak A.
    Microbiol Immunol; 2018 Nov 08; 62(11):711-719. PubMed ID: 30357922
    [Abstract] [Full Text] [Related]

  • 18. Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides.
    Olive C, Hsien K, Horváth A, Clair T, Yarwood P, Toth I, Good MF.
    Vaccine; 2005 Mar 18; 23(17-18):2298-303. PubMed ID: 15755615
    [Abstract] [Full Text] [Related]

  • 19. Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens.
    Olive C, Batzloff M, Horváth A, Clair T, Yarwood P, Toth I, Good MF.
    Infect Immun; 2003 May 18; 71(5):2373-83. PubMed ID: 12704107
    [Abstract] [Full Text] [Related]

  • 20. Immunogenicity of a 30-valent M protein mRNA group A Streptococcus vaccine.
    Finn MB, Penfound TA, Salehi S, Ogega CO, Dold C, Plante O, Dale JB.
    Vaccine; 2024 Sep 17; 42(22):126205. PubMed ID: 39141987
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.